AngioDynamics (ANGO) Q1 2024: MedTech Segment Climbs to 33% of Revenue, Accelerating Margin Shift
AngioDynamics’ first quarter marked a pivotal step in its ongoing MedTech transformation, with the segment now comprising a third of total revenue and driving material gross margin expansion. Strong NanoKnife and Arion growth offset mechanical thrombectomy softness, while management reaffirmed full-year guidance and signaled confidence in clinical milestones ahead. The quarter’s execution supports the company’s capital-efficient strategy, but margin pressures in MedDevice and cash utilization remain key watchpoints for investors.
Summary
- MedTech Mix Shift: High-margin MedTech platforms now account for a third of total revenue, accelerating the company’s margin expansion strategy.
- Clinical Milestones Advance: NanoKnife and AlphaVac progress underpin future growth opportunities, with pivotal data and regulatory submissions on the horizon.
- Margin and Cash Discipline: Inflation and MedDevice mix weighed on gross margin, but management maintains a disciplined capital allocation stance.
Business Overview
AngioDynamics develops, manufactures, and sells medical devices and minimally invasive technologies for the treatment of peripheral vascular disease, cancer, and other chronic conditions. The company operates two primary segments: MedTech, high-growth, high-margin platforms (NanoKnife, Arion, AlphaVac, AngioVac), and MedDevice, legacy device portfolio (vascular access, ports, ablation, angiographic catheters). Revenue is generated from device sales, disposables, and procedural platforms to hospitals and interventional specialists worldwide.
Performance Analysis
AngioDynamics delivered 5.7% year-over-year revenue growth in Q1, with MedTech platforms expanding 13.3% and now representing 33% of total revenue, up from 31% last year. The MedTech segment’s robust performance was led by NanoKnife, which grew 36%, and Arion, which rose 26%. Notably, NanoKnife probe sales were up 35%, with international NanoKnife disposables surging 44% and U.S. disposables up 28%.
MedDevice segment growth was modest at 2.3%, but critical to the company’s cash flow and earnings stability. Mechanical thrombectomy revenue (AngioVac, AlphaVac) declined 5.8% year-over-year, with AlphaVac described as “stuck in first gear,” though sequential stabilization in AngioVac was noted. Gross margin was 50.8%, flat year-over-year, as MedTech margin gains (up 150 basis points to 64.7%) were offset by MedDevice margin contraction from raw material inflation and international mix. Operating cash usage was elevated at $25.9 million, consistent with Q1 seasonal patterns and working capital timing.
- MedTech Margin Accretion: MedTech gross margin rose to 64.7%, supporting the company’s long-term shift to higher-margin platforms.
- NanoKnife and Arion Outperformance: Both platforms posted double-digit growth, validating focused R&D and clinical investment.
- Mechanical Thrombectomy Drag: AlphaVac and AngioVac softness weighed on segment results, but management expects improvement with new indications and design enhancements in 2024.
Adjusted net loss and EBITDA improved year-over-year, but the company remains in investment mode as it pursues pivotal clinical studies and portfolio innovation. Cash balances are expected to build through the year, with management projecting positive cash flow exiting FY25.
Executive Commentary
"Our NanoKnife business performed very well and grew approximately 36% during the first quarter, with sales of probes growing 35%. NanoKnife growth was strong again internationally as our international team continues to establish new relationships with partners who assist in supporting our procedures."
Jim Clemmer, President and Chief Executive Officer
"Our strategic business model contemplates gross margin expansion as our high margin MedTech segment continues to become a larger portion of our overall revenue base. The next phase of our transformation is to address the scale and structural limitations of our operating footprint in a capital-efficient manner, which will reduce the impacts of many of the raw material and inflationary headwinds that we've seen recently."
Steve Trowbridge, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. MedTech Platform Expansion
The company’s transformation hinges on scaling its MedTech platforms, particularly NanoKnife, Arion, and mechanical thrombectomy devices. NanoKnife’s strong international and U.S. growth, coupled with the completion of the PRESERVE study enrollment, positions the platform for an expanded prostate indication and entry into a $700 million U.S. market.
2. Clinical Data and Regulatory Milestones
AngioDynamics is investing heavily in clinical trials and regulatory submissions to support expanded indications and physician adoption. The PRESERVE study (NanoKnife in prostate) and APEX PE study (AlphaVac for pulmonary embolism) are both nearing key data readouts and FDA submissions in 2024. These milestones are critical for unlocking new market opportunities and accelerating platform adoption.
3. Margin Expansion via Mix Shift
The shift toward higher-margin MedTech products is driving corporate gross margin expansion. As MedTech’s share of revenue grows, the company expects continued margin accretion, offsetting inflationary headwinds in the MedDevice segment. Management is also focused on operational efficiency and footprint optimization to further enhance margins.
4. Capital Discipline and Cash Flow Focus
Despite ongoing investment in innovation and clinical programs, AngioDynamics maintains a disciplined approach to capital allocation. The MedDevice segment provides stable cash flow to fund MedTech growth, while management expects to be cash flow positive exiting FY25. The company is not prioritizing share buybacks at this stage, preferring to retain balance sheet flexibility.
5. International Growth Leveraging Partnerships
International markets delivered 26% growth, with a strategy centered on leveraging local partners rather than building a direct sales force. This approach enables capital efficiency while expanding the reach of both MedTech and MedDevice products.
Key Considerations
This quarter underscores AngioDynamics’ progress in its high-margin MedTech transformation, but also highlights the ongoing challenge of balancing innovation investment with profitability and cash flow discipline.
Key Considerations:
- MedTech Momentum: Continued strong growth in NanoKnife and Arion validates the company’s platform strategy and supports future margin expansion.
- Mechanical Thrombectomy Execution: Stabilizing AngioVac and upcoming AlphaVac enhancements are critical for segment recovery and market share gains.
- Clinical and Regulatory Catalysts: PRESERVE and APEX PE studies represent pivotal milestones for market expansion and product adoption.
- Margin Leverage and Cost Pressures: Inflation and MedDevice mix remain headwinds, but MedTech mix shift is a structural tailwind.
- Capital Allocation Discipline: Management’s measured approach to cash utilization and portfolio management provides stability during transformation.
Risks
Key risks include potential delays in clinical trial enrollment or regulatory approvals, which could push out anticipated market expansions. Inflationary pressures and unfavorable product mix in MedDevice may continue to weigh on gross margin, while ongoing cash burn and the need for capital to fund innovation could limit near-term profitability. Competitive intensity in mechanical thrombectomy and evolving reimbursement dynamics also pose challenges to execution.
Forward Outlook
For Q2, AngioDynamics guided to:
- Continued revenue and margin improvement, driven by MedTech growth and operational efficiency
- Stable MedDevice performance, with incremental margin headwinds from raw material costs
For full-year 2024, management maintained guidance:
- Revenue of $328 million to $333 million
- Adjusted loss per share of $0.28 to $0.34
- Gross margin of 50% to 52%
- MedTech revenue growth of 20% to 25%; MedDevice growth of 1% to 3%
Management highlighted several factors that will shape results:
- Completion and publication of pivotal clinical data for NanoKnife and AlphaVac
- Ongoing inflationary pressures and cost discipline in MedDevice
Takeaways
AngioDynamics’ Q1 demonstrates tangible progress in its high-margin MedTech pivot, with clinical and operational milestones supporting a credible path to sustainable growth and margin expansion.
- MedTech Platform Execution: Growth in NanoKnife and Arion, combined with advancing clinical trials, positions the company for future revenue and margin gains.
- Margin Structure Evolution: The ongoing mix shift to MedTech is structurally accretive, though inflation and MedDevice mix are near-term headwinds.
- Watch for Clinical Data and Cash Trajectory: Investors should monitor clinical readouts, regulatory progress, and cash flow inflection points as key drivers of valuation and strategic flexibility in coming quarters.
Conclusion
AngioDynamics’ first quarter reflects disciplined execution on its MedTech transformation, with strong platform growth and advancing clinical catalysts offsetting legacy segment pressures. Margin expansion and cash discipline remain central to the investment thesis, with pivotal data and regulatory milestones expected to unlock further upside.
Industry Read-Through
AngioDynamics’ performance highlights the sector-wide imperative to shift toward high-margin, clinically differentiated platforms, as legacy device portfolios face inflation and pricing pressure. Clinical data generation and regulatory milestones are increasingly the gating factors for market access and adoption in medtech, with capital-efficient international expansion a growing trend. Competitors in mechanical thrombectomy and focal therapy should expect intensifying innovation cycles, while the importance of portfolio balance and cash flow discipline will remain central in the face of macro cost pressures.